Table 2.
KM Analysis of Time to Switch to Another Originator Biologic (Including Originator IFX) for the RA and IBD Subgroups
| 0 Months | 3 Months | 6 Months | 9 Months | 12 Months | 18 Months | |
|---|---|---|---|---|---|---|
| RA subgroup | ||||||
| Prevalent population | ||||||
| KM rates (95% CI) | ||||||
| Switchers | 100.00% | 91.1% (88.0, 93.4) | 83.4% (79.4, 86.8) | 76.3% (71.5, 80.4) | 70.3% (65.0, 75.0) | 67.2% (61.5, 72.3) |
| Continuers | 100.00% | 97.3% (96.3, 98.1) | 94.3% (92.7, 95.5) | 92.2% (90.3, 93.7) | 90.8% (88.7, 92.5) | 89.2% (86.8, 91.2) |
| P-value of Log rank test | – | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* |
| Incident population | ||||||
| KM rates (95% CI) | ||||||
| Switchers | 100.00% | 91.7% (86.9, 94.7) | 83.4% (77.1, 88.1) | 75.7% (68.2, 81.7) | 73.8% (66.0, 80.1) | 69.5% (60.5, 76.9) |
| Continuers | 100.00% | 96.2% (94.3, 97.4) | 93.0% (90.5, 94.9) | 90.0% (86.9, 92.4) | 88.6% (85.2, 91.3) | 82.4% (77.3, 86.5) |
| P-value of Log rank test | – | 0.008* | <0.001* | <0.001* | <0.001 * | <0.001* |
| IBD subgroup | ||||||
| Prevalent population | ||||||
| KM rates (95% CI) | ||||||
| Switchers | 100.00% | 86.1% (82.6, 89.0) | 80.9% (76.8, 84.4) | 78.0% (73.6, 81.9) | 73.3% (68.1, 77.8) | 70.1% (64.2, 75.3) |
| Continuers | 100.00% | 97.9% (97.0, 98.5) | 95.3% (93.9, 96.4) | 93.7% (92.1, 95.0) | 92.1% (90.2, 93.7) | 90.3% (87.9, 92.2) |
| P-value of Log rank test | – | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* |
| Incident population | ||||||
| KM rates (95% CI) | ||||||
| Switchers | 100.00% | 84.7% (79.4, 88.7) | 80.4% (74.4, 85.0) | 78.2% (71.9, 83.3) | 72.3% (64.7, 78.6) | 65.0% (54.8, 73.4) |
| Continuers | 100.00% | 96.6% (95.0, 97.7) | 94.7% (92.6, 96.2) | 92.9% (90.4, 94.7) | 89.2% (86.0, 91.8) | 87.6% (83.8, 90.6) |
| P-value of Log rank test | – | <0.001* | <0.001* | <0.001* | <0.001* | <0.001* |
Note: *p<0.05.
Abbreviations: CI, confidence interval; IBD, inflammatory bowel disease; KM, Kaplan–Meier; RA, rheumatoid arthritis.